An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Breaking news
An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
